Heterocyclic compounds

1. A compound represented by the formula (I):

wherein

R 1 and R 2 are each independently a hydrogen atom or a substituent, or R 1 and R 2 are bonded to each other to form, together with the adjacent nitrogen atom, a non-aromatic nitrogen-containing heterocycle that is unsubstituted or that is substituted with from one to three substituents independently selected from Substituent Group A,

R 3 is a C 1-6 alkyl group that is unsubstituted or that is substituted with from one to five substituents independently selected from Substituent Group A,

X is CR 4 or N,

R 4 , R 5 and R 6 are each independently a hydrogen atom, a halogen atom, a C 1-6 alkyl group that is unsubstituted or that is substituted with from one to five substituents independently selected from Substituent Group A or a C 1-6 alkoxy group that is unsubstituted or that is substituted with from one to five substituents independently selected from Substituent Group A, and

Ring A is a 6-membered aromatic ring optionally further substituted by 1 to 4 substituents selected from (i) a halogen atom, (ii) a C 1-6 alkyl group and (iii) a C 1-6 alkoxy group,

or a salt thereof,

wherein Substituent Group A is the group consisting of:

(1) a halogen atom,

(2) a nitro group,

(3) a cyano group,

(4) an oxo group,

(5) a hydroxy group,

(6) a C 1-6 alkoxy group,

(7) a C 6-14 aryloxy group,

(8) a C 7-16 aralkyloxy group,

(9) a 5- to 14-membered aromatic heterocyclyloxy group,

(10) a 3- to 14-membered non-aromatic heterocyclyloxy group,

(11) a C 1-6 alkyl-carbonyloxy group,

(12) a C 6-14 aryl-carbonyloxy group,

(13) a C 1-6 alkoxy-carbonyloxy group,

(14) a mono- or di-C 1-6 alkyl-carbamoyloxy group,

(15) a C 6-14 aryl-carbamoyloxy group,

(16) a 5- to 14-membered aromatic heterocyclylcarbonyloxy group,

(17) a 3- to 14-membered non-aromatic heterocyclylcarbonyloxy group,

(18) an C 1-6 alkylsulfonyloxy group,

(19) a C 6-14 arylsulfonyloxy group,

(20) an C 1-6 alkylthio group,

(21) a 5- to 14-membered aromatic heterocyclic group,

(22) a 3- to 14-membered non-aromatic heterocyclic group,

(23) a formyl group,

(24) a carboxy group,

(25) an C 1-6 alkyl-carbonyl group,

(26) a C 6-14 aryl-carbonyl group,

(27) a 5- to 14-membered aromatic heterocyclylcarbonyl group,

(28) a 3- to 14-membered non-aromatic heterocyclylcarbonyl group,

(29) a C 1-6 alkoxy-carbonyl group,

(30) a C 6-14 aryloxy-carbonyl group,

(31) a C 7-16 aralkyloxy-carbonyl group,

(32) a carbamoyl group,

(33) a thiocarbamoyl group,

(34) a mono- or di-C 1-6 alkyl-carbamoyl group,

(35) a C 6-14 aryl-carbamoyl group,

(36) a 5- to 14-membered aromatic heterocyclylcarbamoyl group,

(37) a 3- to 14-membered non-aromatic heterocyclylcarbamoyl group,

(38) a C 1-6 alkylsulfonyl group,

(39) a C 6-14 arylsulfonyl group,

(40) a 5- to 14-membered aromatic heterocyclylsulfonyl group,

(41) a C 1-6 alkylsulfinyl group,

(42) a C 6-14 arylsulfinyl group,

(43) a 5- to 14-membered aromatic heterocyclylsulfinyl group,

(44) an amino group,

(45) a mono- or di-C 1-6 alkylamino group,

(46) a mono- or di-C 6-14 arylamino group,

(47) a 5- to 14-membered aromatic heterocyclylamino group,

(48) a C 7-16 aralkylamino group,

(49) a formylamino group,

(50) a C 1-6 alkyl-carbonylamino group,

(51) a (C 1-6 alkyl)(C 1-6 alkyl-carbonyl) amino group,

(52) a C 6-14 aryl-carbonylamino group,

(53) a C 1-6 alkoxy-carbonylamino group,

(54) a C 7-16 aralkyloxy-carbonylamino group,

(55) a C 1-6 alkylsulfonylamino group,

(56) a C 6-14 arylsulfonylamino group,

(57) a C 1-6 alkyl group optionally substituted by 1 to 3 halogen atoms,

(58) a C2-6 alkenyl group,

(59) a C 2-6 alkynyl group,

(60) a C 3-10 cycloalkyl group,

(61) a C 3-10 cycloalkenyl group, and

(62) a C 6-14 aryl group.

2. The compound or salt according to claim 1 , wherein

R 1 and R 2 are each independently

(1) a hydrogen atom,

(2) a C 1-6 alkyl group optionally substituted by 1 to 3 substituents selected from

(a) a cyano group, and

(b) a C 3-10 cycloalkyl group, or

(3) a 3- to 14-membered non-aromatic heterocyclic group, or

R 1 and R 2 are bonded to each other to form, together with the adjacent nitrogen atom, a 3- to 14-membered non-aromatic nitrogen-containing heterocycle optionally further substituted by 1 to 3 substituents selected from

(a) a halogen atom,

(b) a C 1-6 alkyl group optionally substituted by 1 to 3 halogen atoms, and

(c) a C 1-6 alkoxy group;

R 3 is a C 1-6 alkyl group optionally substituted by 1 to 3 substituents selected from

(a) a halogen atom,

(b) a cyano group, and

(c) a C 1-6 alkoxy group;

X is CR 4 or N;

R 4 is

(1) a hydrogen atom,

(2) a halogen atom, or

(3) a C 1-6 alkyl group;

R 5 is

(1) a hydrogen atom, or

(2) a C 1-6 alkyl group;

R 6 is a hydrogen atom; and

Ring A is

(1) a benzene ring optionally further substituted by 1 to 4 substituents selected from (i) a halogen atom, and (ii) a C 1-6 alkoxy group, or

(2) a pyridine ring optionally further substituted by 1 to 4 halogen atoms.

3. The compound or salt according to claim 1 , wherein

R 1 and R 2 are each independently

(1) a hydrogen atom,

(2) a C 1-6 alkyl group optionally substituted by 1 to 3 substituents selected from

(a) a cyano group, and

(b) a C 3-6 cycloalkyl group, or

(3) a tetrahydropyranyl group, or

R 1 and R 2 are bonded to each other to form, together with the adjacent nitrogen atom,

(1) a morpholine ring optionally further substituted by 1 to 3 substituents selected from

(a) a halogen atom, and

(b) a C 1-6 alkyl group optionally substituted by 1 to 3 halogen atoms,

(2) an oxazepane ring optionally further substituted by 1 to 3 halogen atoms,

(3) an azetidine ring optionally further substituted by 1 to 3 halogen atoms,

(4) a pyrrolidine ring optionally further substituted by 1 to 3 C 1-6 alkoxy groups,

(5) a piperidine ring optionally further substituted by 1 to 3 C 1-6 alkoxy groups, or

(6) a 5-oxa-8-azaspiro[2.6]nonane ring;

R 3 is a C 1-6 alkyl group optionally substituted by 1 to 3 substituents selected from

(a) a halogen atom,

(b) a cyano group, and

(c) a C 1-6 alkoxy group;

X is CR 4 or N;

R 4 is

(1) a hydrogen atom,

(2) a halogen atom, or

(3) a C 1-6 alkyl group;

R 5 is

(1) a hydrogen atom, or

(2) a C 1-6 alkyl group;

R 6 is a hydrogen atom; and

Ring A is

(1) a benzene ring optionally further substituted by 1 to 4 substituents selected from (i) a halogen atom, and (ii) a C 1-6 alkoxy group, or

(2) a pyridine ring optionally further substituted by 1 to 4 halogen atoms.

4. The compound or salt according to claim 1 , wherein

R 1 and R 2 are bonded to each other to form, together with the adjacent nitrogen atom,

(1) a morpholine ring, or

(2) an oxazepane ring optionally further substituted by 1 to 3 halogen atoms;

R 3 is a C 1-6 alkyl group substituted by 1 to 3 halogen atoms;

X is CH or N;

R 5 is a hydrogen atom;

R 6 is a hydrogen atom; and

Ring A is

(1) a benzene ring optionally further substituted by 1 or 2 halogen atoms, or

(2) a pyridine ring optionally further substituted by 1 or 2 halogen atoms.

5. The compound or salt according to claim 1 , wherein

R 1 and R 2 are bonded to each other to form, together with the adjacent nitrogen atom,

(1) a morpholine ring, or

(2) an oxazepane ring;

R 3 is a C 1-6 alkyl group substituted by two halogen atoms;

X is CH or N;

R 5 is a hydrogen atom;

R 6 is a hydrogen atom; and

Ring A is

(1) a benzene ring optionally further substituted by one halogen atom, or

(2) a pyridine ring optionally further substituted by one halogen atom.

6. (4-(1-(2,2-Difluoroethyl)-2-(trifluoromethyl)-1 H-imidazo[4,5-c]pyridin-4-yl)-2-fluorophenyl)(morpholin-4-yl)methanone, or a salt thereof.

7. (4-(1-(2,2-Difluoroethyl)-2-(trifluoromethyl)-1 H-imidazo[4,5-c]pyridin-4-yl)-2-fluorophenyl)(1,4-oxazepan-4-yl)methanone, or a salt thereof.

8. (5-(1-(2,2-Difluoroethyl)-2-(trifluoromethyl)-1 H-benzimidazol-4-yl)-3-fluoropyridin-2-yl)(morpholin-4-yl)methanone, or a salt thereof.

9. A pharmaceutical composition comprising the compound or salt according to claim 1 and a pharmacologically acceptable carrier.